Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

436P - Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Colon and Rectal Cancer

Presenters

Daniel Ahn

Citation

Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270

Authors

D.H. Ahn1, M. Erlander2, M. Ridinger2, E. Samuëlsz2, A. Barzi3, T. Bekaii-Saab1, H.J. Lenz4

Author affiliations

  • 1 Medical Oncology Department, Mayo Clinic Cancer Center, 85054 - Phoenix/US
  • 2 R&d, Cardiff Oncology, 92121 - San Diego/US
  • 3 Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 91010 - Duarte/US
  • 4 Medical Oncology Department, USC, University of Southern California - Norris Comprehensive Cancer Center, 90033 - Los Angeles/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 436P

Background

Second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC) confers a dismal patient (pt) outcome with response rates of 4% to FOLFIRI (5-fluorouracil (5FU), leucovorin, irinotecan) + bevacizumab (bev) and median progression-free survival (PFS) of 5.5 months. PLK1 is a serine/threonine kinase, master regulator of mitosis. PLK1 inhibition has synthetic lethality with KRAS-mutated CRC tumor cells. Onvansertib is an oral and highly-selective PLK1 inhibitor with demonstrated efficacy as a single agent and synergistically with irinotecan in CRC preclinical models.

Methods

This single-arm phase Ib/II study (NCT03829410) assesses the safety and preliminary efficacy of onvansertib in combination with FOLFIRI + bev in second line KRAS-mutated mCRC. Pts are treated with onvansertib (days 1-5) + FOLFIRI-bev (day 1) in a 14-day cycle. In the phase Ib, a standard 3 + 3 dose-escalation design is used to determine the maximum tolerated dose or recommended phase II dose. Secondary objectives are preliminary efficacy determined by radiographic scans every 8 weeks and reduction in KRAS mutant allelic burden evaluated by liquid biopsy.

Results

As of May 4, 2020, onvansertib 12 and 15 mg/m2 dose levels were cleared for safety. At dose level 18 mg/m2, 1 of 3 pts had a DLT (G4 neutropenia deemed to be associated with 5FU bolus) and 3 additional pts are enrolling. Most common all-causality adverse events (AEs) were fatigue, diarrhea, nausea and neutropenia. All grade 3/4 AEs resolved within 2.5 weeks and did not result in treatment discontinuation. Of the 9 pts evaluable for efficacy, 4 (44%) had partial response (PR) and 4 (44%) stable disease with 1 pt proceeded to curative surgery followed by no evidence of disease. Median PFS is >6 months to-date, with 6 of the 9 pts remaining on treatment. Decrease in plasma KRAS mutant during the first cycle of treatment was highly predictive of tumor regression.

Conclusions

Preliminary results indicate that onvansertib is safe and efficacious in combination with chemotherapy in KRAS-mutated mCRC pts and early changes in plasma KRAS mutant are predictive of clinical response.

Clinical trial identification

NCT03829410.

Editorial acknowledgement

Legal entity responsible for the study

Cardiff Oncology.

Funding

Cardiff Oncology.

Disclosure

M. Erlander, M. Ridinger, E. Samuëlsz: Shareholder/Stockholder/Stock options, Full/Part-time employment: Cardiff Oncology. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.